Equity Profile

OGN

Organon & Co.

Health CarePharmaceuticals$3.5B

Aug4Tue

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

Organon & Co. is a pharmaceutical company focused on women's health and other therapeutic areas....

Key Metrics to Watch

EPS (Earnings Per Share)

EPS is a key indicator of the company's profitability and is closely watched by investors.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its market presence and product offerings.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

OGN Q2-2026 Earnings Preview

Context

Company Snapshot

Organon & Co. is a pharmaceutical company focused on women's health and other therapeutic areas. With a market cap of $4 billion, it plays a crucial role in developing medications that address significant health issues, particularly for women, in a sector that is increasingly focused on specialized healthcare solutions.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

+7.95%

Avg Stock Reaction

-3.38%

Last Quarter Recap

In Q1 2026, Organon reported an EPS of $0.71, which was below the expected $0.81, resulting in a 0.67% decline in stock price the following day. This miss continues a trend of mixed performance in recent quarters.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall expectations for Organon's upcoming earnings are cautious, given the recent earnings misses and lack of analyst estimates. Investors are looking for signs of recovery in profitability and revenue growth.

Bull Case

If Organon can beat EPS expectations and provide positive updates on its product pipeline, it could signal a turnaround and boost investor confidence.

Bear Case

Conversely, another earnings miss or negative commentary on the product pipeline could lead to further declines in stock price, as investors may lose faith in the company's growth prospects.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the updated EPS figure for Q2-2026?

This number will be critical in assessing whether the company is on track to recover from recent earnings misses.

What updates can management provide on the product pipeline?

Insights into the product pipeline will help investors gauge future revenue potential and the company's competitive position.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for a rebound in Organon's earnings, particularly if the product pipeline shows promising developments.

Supporting Evidence

Options are pricing a 21.36% move, indicating expectations for volatility that may not align with the company's actual performance.

The recent historical trend shows a 75% EPS beat rate, suggesting that the company has the potential to surprise positively.

Key Risk

If the EPS comes in above $0.85, it could significantly shift investor sentiment and challenge the current cautious outlook.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate this quarter revolves around whether Organon can stabilize its earnings after recent misses and provide a clear path for growth.

Bull Confirmed If

An EPS of $0.85 or higher would confirm the bull case and indicate a recovery in profitability.

Bear Confirmed If

An EPS below $0.70 would confirm the bear case and raise concerns about the company's growth trajectory.

Pre-Earnings Positioning

Options Market

Implied Move

±21.36%

Historical Avg

±10.8%

Pricing rich

The options market is pricing in a significant move, suggesting that investors expect volatility around the earnings report.

Options are pricing ±21.4% while OGN has averaged ±10.8% over the last 8 prints — setup is pricing rich.

Detail

30d HV

95.4%

Calls (3K)P/C Ratio: 0.53Puts (52K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich setup in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 3.6%, with a raw directional average of -1.3% (modestly negative historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Organon beats expectations, history suggests the stock could rise by around 3% on the first day, confirming a positive turnaround narrative.

In-Line / Cautious

If results are in line but cautious, the stock may see muted movement as investors digest the commentary, leading to a more stable price.

Miss

If the company misses again, the average historical reaction suggests a decline of about 4%, potentially leading to further investor skepticism.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any specific guidance on upcoming product launches or pipeline developments.
2Management's commentary on cost management and operational efficiency.
3Updates on market share trends in key therapeutic areas.
4Any insights into regulatory challenges or opportunities.
5Discussion on competitive positioning against other pharmaceutical companies.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug3

ONBMO

ON Semiconductor Corporation

PreviewView

Aug3

LBMO

Company Snapshot

Organon & Co. is a pharmaceutical company focused on women's health and other therapeutic areas....

Key Metrics to Watch

EPS (Earnings Per Share)

EPS is a key indicator of the company's profitability and is closely watched by investors.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its market presence and product offerings.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

OGN Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

+7.95%

Avg Stock Reaction

-3.38%

Last Quarter Recap

Management Promises & Guidance

Expectations

Wall Street Expectations

Bull Case

If Organon can beat EPS expectations and provide positive updates on its product pipeline, it could signal a turnaround and boost investor confidence.

Bear Case

Conversely, another earnings miss or negative commentary on the product pipeline could lead to further declines in stock price, as investors may lose faith in the company's growth prospects.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the updated EPS figure for Q2-2026?

This number will be critical in assessing whether the company is on track to recover from recent earnings misses.

What updates can management provide on the product pipeline?

Insights into the product pipeline will help investors gauge future revenue potential and the company's competitive position.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for a rebound in Organon's earnings, particularly if the product pipeline shows promising developments.

Supporting Evidence

Options are pricing a 21.36% move, indicating expectations for volatility that may not align with the company's actual performance.

The recent historical trend shows a 75% EPS beat rate, suggesting that the company has the potential to surprise positively.

Key Risk

If the EPS comes in above $0.85, it could significantly shift investor sentiment and challenge the current cautious outlook.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate this quarter revolves around whether Organon can stabilize its earnings after recent misses and provide a clear path for growth.

Bull Confirmed If

An EPS of $0.85 or higher would confirm the bull case and indicate a recovery in profitability.

Bear Confirmed If

An EPS below $0.70 would confirm the bear case and raise concerns about the company's growth trajectory.

Pre-Earnings Positioning

Options Market

Implied Move

±21.36%

Historical Avg

±10.8%

Pricing rich

The options market is pricing in a significant move, suggesting that investors expect volatility around the earnings report.

Options are pricing ±21.4% while OGN has averaged ±10.8% over the last 8 prints — setup is pricing rich.

Detail

30d HV

95.4%

Calls (3K)P/C Ratio: 0.53Puts (52K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich setup in Health Care

n=30

Fade rate: 13 of 29 (45%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Organon beats expectations, history suggests the stock could rise by around 3% on the first day, confirming a positive turnaround narrative.

In-Line / Cautious

If results are in line but cautious, the stock may see muted movement as investors digest the commentary, leading to a more stable price.

Miss

If the company misses again, the average historical reaction suggests a decline of about 4%, potentially leading to further investor skepticism.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any specific guidance on upcoming product launches or pipeline developments.
2Management's commentary on cost management and operational efficiency.
3Updates on market share trends in key therapeutic areas.
4Any insights into regulatory challenges or opportunities.
5Discussion on competitive positioning against other pharmaceutical companies.